A Phase I open label dose escalation study for the safety and tolerability of AZD2171 in solid tumors in Japan

Study identifier:D8480C00023

ClinicalTrials.gov identifier:NCT00503477

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I open label dose escalation study for the safety and tolerability of AZD2171 following single and multiple oral doses in patients in Japan with advanced solid malignancies

Medical condition

advanced solid tumor

Phase

Phase 1

Healthy volunteers

Study drug

AZD2171

Sex

All

Actual Enrollment

Study type

Interventional

Age

20 Years - 75 Years

Date

Study Start Date: 31 Oct 2005

Primary Completion Date: 31 Jul 2007

Study Completion Date: 31 Jan 2009

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2025 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Tokyo, Japan

Location

Research Site

Shizuoka, Japan

Arms	Assigned Interventions

"There is no result for the study"

Documents available

CSR-D8480C00023.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Jane Robertson

AstraZeneca

A Phase I open label dose escalation study for the safety and tolerability of AZD2171 in solid tumors in Japan

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Research Site

Documents available

CSR-D8480C00023.pdf

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator